A Prospective, Randomized, Double-Masked, Multicenter, Two Arm Study Comparing the Efficacy and Safety of ESBA1008 Versus EYLEA in Subjects With Exudative Age-Related Macular Degeneration

Trial Profile

A Prospective, Randomized, Double-Masked, Multicenter, Two Arm Study Comparing the Efficacy and Safety of ESBA1008 Versus EYLEA in Subjects With Exudative Age-Related Macular Degeneration

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Brolucizumab (Primary) ; Aflibercept
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Sponsors Alcon
  • Most Recent Events

    • 01 Sep 2017 Results assessing the efficacy and safety of brolucizumab with aflibercept to treat neovascular age-related macular degeneration (AMD), were published in the Ophthalmology.
    • 27 Feb 2015 Results presented in 38th Annual Macula Society Meeting in Scottsdale, Arizona, as per Novartis media release.
    • 27 Feb 2015 Primary endpoint has been met. (Best corrected visual acuity (Change from baseline in best-corrected visual acuity.), as per Novartis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top